跳至主要内容
临床试验/EUCTR2019-000326-22-IT
EUCTR2019-000326-22-IT进行中(未招募)1 期

The role of Contrast-Enhanced Spectral Mammography (CESM) in the diagnostic process of breast cancer: can it improve specificity of first-line examinations and therefore reduce the suspicious lesions that undergo vacuum assisted breast biopsy (VABB)? - IEO 960

ISTITUTO EUROPEO DI ONCOLOGIA0 个研究点目标入组 170 人开始时间: 2020年10月21日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
170

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Woman with suspicious breast lesions from FFDM, US and/or MR imaging and for whom a presurgical evaluation is recommended
  • The subject must be in sufficient good health to be able to undergo standard of care and CESM examinations
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 125
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 45

排除标准

  • The subject is known to have risks of adverse effects with iodine contrast agents.
  • The subject is asymptomatic and without suspicious findings from routine imaging.
  • The subject is participating or has participated (within the prior 30 days) in another clinical

研究者

相似试验